What is the status of Empliciti (elotuzumab), the new immunotherapy? (https://www.myeloma.org/videos/status-emplicitir-elotuzumab-new-immunotherapy)
In this week’s video, Dr. Brian G.M. Durie explains the recent FDA approval for the use of elotuzumab, pomalidomide, and dexamethasone (EPd) for the treatment of relapsed or refractory myeloma in patients who have received at least two prior therapies.
BOTTOM LINE:
An important new combination – EPd – is now approved and available.
Ask a Question
Please note that Ask Dr. Durie has been discontinued, and it was designed to address myeloma questions of the broadest possible audience interest. If you have a question of a personal nature, please contact our InfoLine Coordinators at 800.452.2873 or [email protected] (mailto:[email protected]) (Please do not send email attachments or lab reports.).
Dr. Brian G.M. Durie (1942-2025) was the co-founder of the IMF. He was a Professor of Medicine, Hematologist/Oncologist, and Honoree MD at the University of Brussels.